Cox univariate and multivariate analyses also showed that FBXL7 upregulation and pathological stage significantly predicted a poor RFS probability after adjuvant chemotherapy in ovarian serous cystadenocarcinoma (Table 1). The gene discussed is FBXL7; the disease is ovarian serous cystadenocarcinoma.